The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals
Status:
Completed
Trial end date:
2020-11-20
Target enrollment:
Participant gender:
Summary
MicrSoy-20 (MS-20), a fermented soymilk product, has been approved as an Over the counter
(OTC) drug in 2011. The therapeutic effect of MS-20 is to ameliorate symptoms such as fatigue
and loss of appetite caused by cancer chemotherapy. Animal study revealed orally
administration of MS-20 daily for 4 weeks altered the gut microbiota composition in mice. In
addition, MS-20 could activate dendritic cell and improve immunotherapy response rate. Thus,
it was hypothesis that MS-20 improves host immune activity thus ameliorate fatigue and
increase weight is through alteration the gut microbiota composition.
In this study, the ability of MS-20 in modulating gut microbiota and the subset of microbiome
to be altered by MS-20 was investigated.